|
G |
ABCC11 |
ATP binding cassette subfamily C member 11 |
decreases response to substance affects response to substance |
EXP |
ABCC11 mRNA results in decreased susceptibility to Pemetrexed; ABCC11 protein results in decreased susceptibility to Pemetrexed ABCC11 gene SNP affects the susceptibility to Pemetrexed |
CTD |
PMID:20718756 |
|
NCBI chr16:48,164,819...48,247,539
Ensembl chr16:48,165,773...48,247,568
|
|
G |
ABCC5 |
ATP binding cassette subfamily C member 5 |
decreases response to substance |
EXP |
ABCC5 protein results in decreased susceptibility to Pemetrexed |
CTD |
PMID:15897250 |
|
NCBI chr 3:183,919,934...184,017,884
Ensembl chr 3:183,919,934...184,017,939
|
|
G |
ALK |
ALK receptor tyrosine kinase |
affects response to substance |
EXP |
ALK gene mutant form affects the susceptibility to Pemetrexed |
CTD |
PMID:21336183 |
|
NCBI chr 2:29,192,774...29,921,586
Ensembl chr 2:29,192,774...29,921,586
|
|
G |
BBC3 |
BCL2 binding component 3 |
increases expression multiple interactions |
EXP |
Pemetrexed results in increased expression of BBC3 protein xanthohumol promotes the reaction [Pemetrexed results in increased expression of BBC3 protein] |
CTD |
PMID:35259468 |
|
NCBI chr19:47,220,824...47,232,860
Ensembl chr19:47,220,822...47,232,766
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
multiple interactions |
EXP |
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of BCL2 protein |
CTD |
PMID:19351772 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BID |
BH3 interacting domain death agonist |
multiple interactions |
EXP |
[Cisplatin co-treated with Pemetrexed] results in increased cleavage of BID protein |
CTD |
PMID:19351772 |
|
NCBI chr22:17,734,138...17,774,665
Ensembl chr22:17,734,138...17,774,770
|
|
G |
C3 |
complement C3 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein |
CTD |
PMID:22975265 |
|
NCBI chr19:6,677,704...6,720,650
Ensembl chr19:6,677,704...6,730,562
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CCL2 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCND1 |
cyclin D1 |
multiple interactions |
EXP |
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein |
CTD |
PMID:19351772 |
|
NCBI chr11:69,641,156...69,654,474
Ensembl chr11:69,641,156...69,654,474
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
EXP |
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein |
CTD |
PMID:19351772 |
|
NCBI chr 6:36,676,463...36,687,332
Ensembl chr 6:36,676,460...36,687,397
|
|
G |
CFLAR |
CASP8 and FADD like apoptosis regulator |
decreases response to substance |
EXP |
CFLAR results in decreased susceptibility to Pemetrexed |
CTD |
PMID:21726997 |
|
NCBI chr 2:201,116,164...201,176,687
Ensembl chr 2:201,116,154...201,176,687
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CXCL8 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CXCL8 protein |
CTD |
PMID:22975265 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
multiple interactions |
EXP |
DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B] |
CTD |
PMID:21726997 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DHFR |
dihydrofolate reductase |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of DHFR mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 5:80,626,226...80,654,983
Ensembl chr 5:80,626,226...80,654,983
|
|
G |
ERCC1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions decreases expression |
EXP |
Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein] Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein |
CTD |
PMID:23912706 |
|
NCBI chr19:45,407,334...45,451,547
Ensembl chr19:45,407,334...45,478,828
|
|
G |
FAS |
Fas cell surface death receptor |
increases expression multiple interactions |
EXP |
Pemetrexed results in increased expression of FAS protein TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein] |
CTD |
PMID:15161716 |
|
NCBI chr10:88,964,050...89,017,059
Ensembl chr10:88,953,813...89,029,605
|
|
G |
FPGS |
folylpolyglutamate synthase |
increases response to substance |
EXP |
FPGS protein results in increased susceptibility to Pemetrexed |
CTD |
PMID:17575230 |
|
NCBI chr 9:127,802,858...127,814,506
Ensembl chr 9:127,794,597...127,814,494
|
|
G |
GGH |
gamma-glutamyl hydrolase |
affects response to substance |
EXP |
GGH protein affects the susceptibility to Pemetrexed |
CTD |
PMID:17575230 |
|
NCBI chr 8:63,015,079...63,038,806
Ensembl chr 8:63,014,881...63,039,407
|
|
G |
IFI30 |
IFI30 lysosomal thiol reductase |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr19:18,173,813...18,178,117
Ensembl chr19:18,173,162...18,178,117
|
|
G |
IL11 |
interleukin 11 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL11 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr19:55,364,382...55,370,463
Ensembl chr19:55,364,382...55,370,463
|
|
G |
IL13RA2 |
interleukin 13 receptor subunit alpha 2 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL13RA2 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr X:115,003,982...115,017,616
Ensembl chr X:115,003,975...115,019,977
|
|
G |
IL1A |
interleukin 1 alpha |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1A mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 2:112,773,925...112,784,493
Ensembl chr 2:112,773,925...112,784,493
|
|
G |
IL1RL1 |
interleukin 1 receptor like 1 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1RL1 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 2:102,311,563...102,352,356
Ensembl chr 2:102,311,502...102,352,037
|
|
G |
IL32 |
interleukin 32 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL32 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr16:3,065,403...3,069,530
Ensembl chr16:3,065,297...3,082,192
|
|
G |
IL33 |
interleukin 33 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL33 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 9:6,215,149...6,257,983
Ensembl chr 9:6,215,786...6,257,983
|
|
G |
IL7R |
interleukin 7 receptor |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL7R mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 5:35,856,891...35,879,603
Ensembl chr 5:35,852,695...35,879,603
|
|
G |
KLRC1 |
killer cell lectin like receptor C1 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of KLRC1 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr12:10,442,264...10,454,685
Ensembl chr12:10,442,264...10,454,685
|
|
G |
KRAS |
KRAS proto-oncogene, GTPase |
decreases expression increases response to substance |
EXP |
Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein KRAS gene mutant form results in increased susceptibility to Pemetrexed |
CTD |
PMID:24688052 |
|
NCBI chr12:25,205,246...25,250,929
Ensembl chr12:25,205,246...25,250,936
|
|
G |
MTHFD2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
increases response to substance |
EXP |
MTHFD2 protein results in increased susceptibility to Pemetrexed |
CTD |
PMID:24688052 |
|
NCBI chr 2:74,198,615...74,217,565
Ensembl chr 2:74,186,172...74,217,565
|
|
G |
NPM1 |
nucleophosmin 1 |
decreases response to substance |
EXP |
NPM1 protein results in decreased susceptibility to Pemetrexed |
CTD |
PMID:24736981 |
|
NCBI chr 5:171,387,116...171,410,900
Ensembl chr 5:171,387,116...171,411,810
|
|
G |
NRAS |
NRAS proto-oncogene, GTPase |
increases response to substance |
EXP |
NRAS gene mutant form results in increased susceptibility to Pemetrexed |
CTD |
PMID:24688052 |
|
NCBI chr 1:114,704,469...114,716,771
Ensembl chr 1:114,704,469...114,716,771
|
|
G |
RBM17 |
RNA binding motif protein 17 |
decreases response to substance |
EXP |
RBM17 protein results in decreased susceptibility to Pemetrexed |
CTD |
PMID:16061639 |
|
NCBI chr10:6,089,034...6,117,447
Ensembl chr10:6,089,034...6,117,457
|
|
G |
SLC19A1 |
solute carrier family 19 member 1 |
multiple interactions increases response to substance |
EXP |
Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate] SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed |
CTD |
PMID:16505119 PMID:21879757 |
|
NCBI chr21:45,502,517...45,563,025
Ensembl chr21:45,493,572...45,573,365
|
|
G |
SLC46A1 |
solute carrier family 46 member 1 |
multiple interactions increases response to substance increases activity |
EXP |
Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate] SLC46A1 protein results in increased susceptibility to Pemetrexed Pemetrexed results in increased activity of SLC46A1 protein |
CTD |
PMID:21879757 |
|
NCBI chr17:28,394,642...28,406,592
Ensembl chr17:28,394,642...28,407,197
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFAIP3 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
|
|
G |
TNFRSF10B |
TNF receptor superfamily member 10b |
multiple interactions increases expression |
EXP |
DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B] |
CTD |
PMID:21726997 |
|
NCBI chr 8:23,020,133...23,069,031
Ensembl chr 8:23,020,133...23,069,031
|
|
G |
TNFRSF9 |
TNF receptor superfamily member 9 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFRSF9 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 1:7,915,871...7,940,839
Ensembl chr 1:7,915,871...7,943,165
|
|
G |
TP53 |
tumor protein p53 |
multiple interactions affects response to substance |
EXP |
TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein] TP53 protein affects the susceptibility to Pemetrexed |
CTD |
PMID:15161716 PMID:17339891 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TRAF1 |
TNF receptor associated factor 1 |
multiple interactions |
EXP |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TRAF1 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 9:120,902,393...120,929,171
Ensembl chr 9:120,902,393...120,929,173
|
|
G |
TYMP |
thymidine phosphorylase |
increases response to substance |
EXP |
TYMP protein results in increased susceptibility to Pemetrexed |
CTD |
PMID:17575230 |
|
NCBI chr22:50,525,752...50,530,085
Ensembl chr22:50,525,752...50,530,032
|
|
G |
TYMS |
thymidylate synthetase |
decreases activity affects response to substance multiple interactions |
EXP |
Pemetrexed results in decreased activity of TYMS protein TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein] |
CTD |
PMID:15161716 PMID:17339891 PMID:21742432 |
|
NCBI chr18:657,653...673,578
Ensembl chr18:657,653...673,578
|
|